ALX ONCOLOGY HOLDINGS INC Operating Expenses
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Operating Expenses of $18.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC operating expenses for the quarter ending 2026-06-30 was $18.03M, a 32.33% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC operating expenses for the quarter ending 2026-03-31 was $18.97M, a 40.40% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC operating expenses for the quarter ending 2025-12-31 was $23.02M, a 24.80% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC operating expenses for the quarter ending 2025-09-30 was $22.53M, a 30.81% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC operating expenses for fiscal 2025 was $104.02M, a 26.99% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC operating expenses for fiscal 2024 was $142.47M, a 16.33% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC operating expenses for fiscal 2023 was $170.28M, a 33.62% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC operating expenses for fiscal 2022 was $127.44M, a 52.52% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.03M 10-Q · filed 2026-08-06 | $37.00M 10-Q · filed 2026-08-06 | $60.02M derived: sum of 3 quarters · filed 2026-08-06 | $82.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.97M 10-Q · filed 2026-05-08 | $41.99M derived: sum of 2 quarters · filed 2026-05-08 | $64.52M derived: sum of 3 quarters · filed 2026-05-08 | $91.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $45.55M derived: sum of 2 quarters · filed 2026-03-09 | $72.20M derived: sum of 3 quarters · filed 2026-08-06 | $104.02M 10-K · filed 2026-03-09 |
| 2025-09-30 | $22.53M 10-Q · filed 2025-11-07 | $49.18M derived: sum of 2 quarters · filed 2026-08-06 | $81.00M 10-Q · filed 2025-11-07 | $111.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $26.65M 10-Q · filed 2026-08-06 | $58.47M 10-Q · filed 2026-08-06 | $89.08M derived: sum of 3 quarters · filed 2026-08-06 | $121.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $31.82M 10-Q · filed 2026-05-08 | $62.43M derived: sum of 2 quarters · filed 2026-05-08 | $95.00M derived: sum of 3 quarters · filed 2026-05-08 | $136.53M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $30.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $63.18M derived: sum of 2 quarters · filed 2026-03-09 | $104.70M derived: sum of 3 quarters · filed 2026-03-09 | $142.47M 10-K · filed 2026-03-09 |
| 2024-09-30 | $32.57M 10-Q · filed 2025-11-07 | $74.09M derived: sum of 2 quarters · filed 2025-11-07 | $111.85M 10-Q · filed 2025-11-07 | $159.88M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $41.52M 10-Q · filed 2025-08-12 | $79.29M 10-Q · filed 2025-08-12 | $127.31M derived: sum of 3 quarters · filed 2026-03-09 | $180.59M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $37.76M 10-Q · filed 2025-05-08 | $85.78M derived: sum of 2 quarters · filed 2026-03-09 | $139.06M derived: sum of 3 quarters · filed 2026-03-09 | $175.84M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $48.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $101.30M derived: sum of 2 quarters · filed 2026-03-09 | $138.07M derived: sum of 3 quarters · filed 2026-03-09 | $170.28M 10-K · filed 2026-03-09 |
| 2023-09-30 | $53.27M 10-Q · filed 2024-11-07 | $90.05M derived: sum of 2 quarters · filed 2024-11-07 | $122.25M 10-Q · filed 2024-11-07 | $154.47M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $36.78M 10-Q · filed 2024-08-12 | $68.98M 10-Q · filed 2024-08-12 | $101.20M derived: sum of 3 quarters · filed 2025-03-06 | $137.88M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $32.20M 10-Q · filed 2024-05-09 | $64.42M derived: sum of 2 quarters · filed 2025-03-06 | $101.10M derived: sum of 3 quarters · filed 2025-03-06 | $134.89M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $32.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $68.90M derived: sum of 2 quarters · filed 2025-03-06 | $102.69M derived: sum of 3 quarters · filed 2025-03-06 | $127.44M 10-K · filed 2025-03-06 |
| 2022-09-30 | $36.68M 10-Q · filed 2023-11-13 | $70.47M derived: sum of 2 quarters · filed 2023-11-13 | $95.22M 10-Q · filed 2023-11-13 | $123.69M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $33.79M 10-Q · filed 2023-08-10 | $58.54M 10-Q · filed 2023-08-10 | $87.01M derived: sum of 3 quarters · filed 2024-03-07 | $111.58M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $24.75M 10-Q · filed 2023-05-11 | $53.22M derived: sum of 2 quarters · filed 2024-03-07 | $77.80M derived: sum of 3 quarters · filed 2024-03-07 | $94.09M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $28.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $53.05M derived: sum of 2 quarters · filed 2024-03-07 | $69.35M derived: sum of 3 quarters · filed 2024-03-07 | $83.56M 10-K · filed 2024-03-07 |
| 2021-09-30 | $24.58M 10-Q · filed 2022-11-08 | $40.88M derived: sum of 2 quarters · filed 2022-11-08 | $55.08M 10-Q · filed 2022-11-08 | $72.91M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $16.30M 10-Q · filed 2022-08-08 | $30.51M 10-Q · filed 2022-08-08 | $48.33M derived: sum of 3 quarters · filed 2022-08-08 | $58.14M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $14.21M 10-Q · filed 2022-05-09 | $32.03M derived: sum of 2 quarters · filed 2022-05-09 | $41.84M derived: sum of 3 quarters · filed 2022-05-09 | $53.16M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $17.82M 10-K · filed 2021-03-18 | $27.63M derived: sum of 2 quarters · filed 2021-11-12 | $38.95M derived: sum of 3 quarters · filed 2021-11-12 | $44.84M 10-K · filed 2023-03-09 |
| 2020-09-30 | $9.81M 10-Q · filed 2021-11-12 | $21.12M derived: sum of 2 quarters · filed 2021-11-12 | $27.02M 10-Q · filed 2021-11-12 | $35.97M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $11.31M 10-Q · filed 2021-08-12 | $17.21M 10-Q · filed 2021-08-12 | $26.16M derived: sum of 3 quarters · filed 2021-08-12 | $30.45M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $5.90M 10-Q · filed 2021-05-17 | $14.84M derived: sum of 2 quarters · filed 2021-05-17 | $19.13M derived: sum of 3 quarters · filed 2021-05-17 | $24.62M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $8.95M 10-K · filed 2021-03-18 | $13.24M derived: sum of 2 quarters · filed 2021-03-18 | $18.72M derived: sum of 3 quarters · filed 2021-03-18 | $23.98M 10-K · filed 2022-02-28 |
| 2019-09-30 | $4.29M 10-K · filed 2021-03-18 | $9.77M derived: sum of 2 quarters · filed 2021-03-18 | $15.03M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $5.48M 10-K · filed 2021-03-18 | $10.74M 10-Q · filed 2020-08-27 | ||
| 2019-03-31 | $5.26M 10-K · filed 2021-03-18 | |||
| 2018-12-31 | $15.75M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |